Free Trial
NASDAQ:AXDX

Accelerate Diagnostics (AXDX) Stock Price, News & Analysis

Accelerate Diagnostics logo
$0.53 +0.02 (+4.31%)
As of 10:28 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Accelerate Diagnostics Stock (NASDAQ:AXDX)

Key Stats

Today's Range
$0.54
$0.54
50-Day Range
$0.51
$1.18
52-Week Range
$0.49
$2.09
Volume
1,635 shs
Average Volume
58,888 shs
Market Capitalization
$13.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Strong Buy

Company Overview

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

Accelerate Diagnostics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
55th Percentile Overall Score

AXDX MarketRank™: 

Accelerate Diagnostics scored higher than 55% of companies evaluated by MarketBeat, and ranked 637th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Accelerate Diagnostics are expected to grow in the coming year, from ($2.30) to ($2.00) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Accelerate Diagnostics is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Accelerate Diagnostics is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Accelerate Diagnostics' valuation and earnings.
  • Percentage of Shares Shorted

    1.91% of the float of Accelerate Diagnostics has been sold short.
  • Short Interest Ratio / Days to Cover

    Accelerate Diagnostics has a short interest ratio ("days to cover") of 7.
  • Change versus previous month

    Short interest in Accelerate Diagnostics has recently decreased by 18.44%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Accelerate Diagnostics does not currently pay a dividend.

  • Dividend Growth

    Accelerate Diagnostics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.91% of the float of Accelerate Diagnostics has been sold short.
  • Short Interest Ratio / Days to Cover

    Accelerate Diagnostics has a short interest ratio ("days to cover") of 7.
  • Change versus previous month

    Short interest in Accelerate Diagnostics has recently decreased by 18.44%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Accelerate Diagnostics has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Accelerate Diagnostics this week, compared to 1 article on an average week.
  • MarketBeat Follows

    1 people have added Accelerate Diagnostics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Accelerate Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,885.00 in company stock.

  • Percentage Held by Insiders

    43.60% of the stock of Accelerate Diagnostics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 17.14% of the stock of Accelerate Diagnostics is held by institutions.

  • Read more about Accelerate Diagnostics' insider trading history.
Receive AXDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accelerate Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

AXDX Stock News Headlines

The next market Nvidia is positioned to dominate …
Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang said, "The ChatGPT moment for robotics is right around the corner." In fact, I believe these robots could impact 65 million Americans lives — this year. And one stock — currently priced around $7 — could be the biggest winner.
See More Headlines

AXDX Stock Analysis - Frequently Asked Questions

Accelerate Diagnostics' stock was trading at $1.20 at the start of the year. Since then, AXDX shares have decreased by 57.5% and is now trading at $0.51.
View the best growth stocks for 2025 here
.

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) posted its quarterly earnings data on Thursday, March, 20th. The medical research company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.13. The medical research company had revenue of $2.82 million for the quarter, compared to the consensus estimate of $3 million.

Shares of Accelerate Diagnostics reverse split on the morning of Wednesday, July 12th 2023. The 1-10 reverse split was announced on Wednesday, July 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Accelerate Diagnostics' top institutional investors include Griffin Asset Management Inc. (3.38%). Insiders that own company stock include Jack Phillips, Larry Michael Mertz, David Patience and Steven Reichling.
View institutional ownership trends
.

Shares of AXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Accelerate Diagnostics investors own include Himax Technologies (HIMX), Sangamo Therapeutics (SGMO), Magnachip Semiconductor (MX), Universal Display (OLED), Energy Transfer (ET), Fluidigm (FLDM) and Netflix (NFLX).

Company Calendar

Last Earnings
3/20/2025
Today
5/02/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Analytical instruments
Sub-Industry
Measuring And Control Equipment
Current Symbol
NASDAQ:AXDX
Employees
220
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-61,620,000.00
Net Margins
-471.83%
Pretax Margin
-444.14%

Debt

Sales & Book Value

Annual Sales
$11.70 million
Price / Cash Flow
N/A
Book Value
($1.37) per share
Price / Book
-0.37

Miscellaneous

Free Float
14,125,000
Market Cap
$12.86 million
Optionable
Optionable
Beta
0.46

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:AXDX) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners